A Japanese health ministry panel gave the green light Thursday for the manufacture and sale of the Alzheimer's drug donanemab-azbt, developed by U.S. pharmaceutical giant Eli Lilly and Co.After the soon-to-come formal approval by the Ministry of Health, Labor and Welfare, the drug, under the brand name Kisunla, will become the second medicine available in Japan for treating early symptomatic Alzheimer's disease. The drug works by removing accumulated amyloid beta proteins in the brain, slowing the progress of the disease.Lecanemab, another immunotherapy drug developed by Japan's Eisai Co. a…READ FULL ARTICLE
